Identification

Name
Guanfacine
Accession Number
DB01018  (APRD00075)
Type
Small Molecule
Groups
Approved, Investigational
Description

A centrally acting antihypertensive agent. The drug lowers both systolic and diastolic blood pressure by activating the central nervous system alpha-2 adrenoreceptors, which results in reduced sympathetic outflow leading to reduced vascular tone. Its adverse reactions include dry mouth, sedation, and constipation. [PubChem]

Structure
Thumb
Synonyms
  • Estulic
  • Guanfacina
  • Guanfacinum
External IDs
SPD 503
Product Ingredients
IngredientUNIICASInChI Key
Guanfacine HydrochloridePML56A160O29110-48-3DGFYECXYGUIODH-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
IntunivKitShire2009-09-02Not applicableUs
IntunivTablet, extended release1 mg/1OralTYA Pharmaceuticals2009-09-02Not applicableUs
IntunivTablet, extended release3 mgOralShire2015-09-17Not applicableEu
IntunivTablet, extended release1 mgOralShire2015-09-17Not applicableEu
IntunivTablet, extended release2 mg/1OralShire2009-09-02Not applicableUs54092 0515 02 nlmimage10 071603e0
IntunivTablet, extended release4 mgOralShire2015-09-17Not applicableEu
IntunivTablet, extended release2 mgOralShire2015-09-17Not applicableEu
IntunivTablet, extended release4 mg/1OralShire2009-09-02Not applicableUs54092 0519 02 nlmimage10 fd15feaf
IntunivTablet, extended release1 mg/1OralShire2009-09-02Not applicableUs54092 0513 02 nlmimage10 011600e0
IntunivTablet, extended release2 mgOralShire2015-09-17Not applicableEu
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
GuanfacineTablet2 mg/1OralEpic Pharma, LLC2013-12-02Not applicableUs
GuanfacineTablet1 mg/1OralPura Cap Laboratories Llc Dba Blu Pharmaceuticals2016-11-14Not applicableUs
GuanfacineTablet, extended release2 mg/1OralActavis Pharma Company2014-12-01Not applicableUs00228 2851 11 nlmimage10 113e08a0
GuanfacineTablet1 mg/1OralPhysicians Total Care, Inc.1995-10-17Not applicableUs
GuanfacineTablet, extended release1 mg/1OralAv Kare, Inc.2015-07-07Not applicableUs
GuanfacineTablet, extended release4 mg/1OralTeva2015-06-02Not applicableUs00093 5964 01 nlmimage10 d743ebaf
GuanfacineTablet2 mg/1OralActavis Pharma Company1995-10-17Not applicableUs00591 0453 01 nlmimage10 7207b90d
GuanfacineTablet1 mg/1OralMylan Pharmaceuticals1997-01-27Not applicableUs
GuanfacineTablet, extended release4 mg/1OralActavis Pharma Company2014-12-01Not applicableUs00228 2855 11 nlmimage10 0b4085f4
GuanfacineTablet1 mg/1OralCardinal Health1997-01-272018-02-03Us
International/Other Brands
Estulic (Egis)
Categories
UNII
30OMY4G3MK
CAS number
29110-47-2
Weight
Average: 246.093
Monoisotopic: 245.012267339
Chemical Formula
C9H9Cl2N3O
InChI Key
INJOMKTZOLKMBF-UHFFFAOYSA-N
InChI
InChI=1S/C9H9Cl2N3O/c10-6-2-1-3-7(11)5(6)4-8(15)14-9(12)13/h1-3H,4H2,(H4,12,13,14,15)
IUPAC Name
N-carbamimidoyl-2-(2,6-dichlorophenyl)acetamide
SMILES
NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl

Pharmacology

Indication

For use alone or in combination with other classes of antihypertensive agents in the management of hypertension. Has also been used for the treatment of attention deficit hyperactivity disorder (ADHD) in pediatric patients.

Associated Conditions
Pharmacodynamics

Guanfacine is a phenylacetyl-guanidine derivative hypotensive and a centrally-acting, alpha(2)-adrenergic receptor agonist used alone or in combination with other drugs for the treatment of hypertension.

Mechanism of action

Guanfacine selectively stimulates central alpha(2)-adrenergic receptors, resulting in inhibition of sympathetic vasomotor centers, which contributes predominantly to the hypotensive effects of the drug. Central effects of guanfacine lead to reduced peripheral sympathetic nerve impulses from the vasomotor center to the heart and blood vessels. This results in a decrease in peripheral vascular resistance and a reduction in heart rate. The stimulation of peripheral alpha(2)-adrenergic receptors may also contribute to hypotensive effects.

TargetActionsOrganism
AAlpha-2A adrenergic receptor
agonist
Human
UAlpha-2B adrenergic receptor
binder
Human
Absorption

Rapid and complete, with an oral bioavailability of approximately 80%.

Volume of distribution
  • 6.3 L/kg
Protein binding

Approximately 70% bound to plasma proteins, independent of drug concentration.

Metabolism

Hepatic

Route of elimination

In individuals with normal renal function, guanfacine and its metabolites are excreted primarily in the urine.

Half life

17 hours (range 10-30 hours)

Clearance
Not Available
Toxicity

Symptoms of overdose include drowsiness, lethargy, bradycardia and hypotension. LD50=165mg/kg (orally in mice)

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when Guanfacine is combined with 7-Nitroindazole.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Guanfacine.Experimental
AbirateroneThe metabolism of Guanfacine can be decreased when combined with Abiraterone.Approved
AcebutololGuanfacine may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved, Investigational
AcemetacinThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
AcepromazineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Aceprometazine.Approved
Acetyl sulfisoxazoleThe metabolism of Guanfacine can be decreased when combined with Acetyl sulfisoxazole.Approved, Vet Approved
AdipiplonThe risk or severity of adverse effects can be increased when Guanfacine is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Guanfacine is combined with Alaproclate.Experimental
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Guanfacine.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Guanfacine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Guanfacine.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Guanfacine.Approved, Investigational
AliskirenGuanfacine may increase the hypotensive activities of Aliskiren.Approved, Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Guanfacine is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Guanfacine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Guanfacine.Approved, Illicit, Investigational
AlprenololGuanfacine may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved, Withdrawn
AmbrisentanGuanfacine may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineGuanfacine may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Guanfacine.Approved
AmineptineAmineptine may decrease the antihypertensive activities of Guanfacine.Illicit, Withdrawn
AmiodaroneThe serum concentration of Guanfacine can be increased when it is combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Guanfacine is combined with Amisulpride.Approved, Investigational
AmitriptylineAmitriptyline may decrease the antihypertensive activities of Guanfacine.Approved
AmitriptylinoxideAmitriptylinoxide may decrease the antihypertensive activities of Guanfacine.Approved, Investigational
AmlodipineGuanfacine may increase the hypotensive activities of Amlodipine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Guanfacine.Approved, Illicit
AmoxapineAmoxapine may decrease the antihypertensive activities of Guanfacine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Guanfacine is combined with Amperozide.Experimental
AmphetamineAmphetamine may increase the hypotensive activities of Guanfacine.Approved, Illicit, Investigational
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Guanfacine.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Guanfacine is combined with Amyl Nitrite.Approved
ApalutamideThe serum concentration of Guanfacine can be decreased when it is combined with Apalutamide.Approved, Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Guanfacine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Guanfacine.Approved
AprepitantThe serum concentration of Guanfacine can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Guanfacine.Approved, Investigational
ArmodafinilThe metabolism of Guanfacine can be decreased when combined with Armodafinil.Approved, Investigational
ArotinololGuanfacine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Guanfacine.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Articaine.Approved
AsenapineGuanfacine may increase the atrioventricular blocking (AV block) activities of Asenapine.Approved
AtazanavirThe serum concentration of Guanfacine can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololGuanfacine may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved
AtomoxetineThe metabolism of Guanfacine can be decreased when combined with Atomoxetine.Approved
AvanafilAvanafil may increase the antihypertensive activities of Guanfacine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Guanfacine is combined with Azaperone.Investigational, Vet Approved
AzelastineGuanfacine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Guanfacine is combined with Azilsartan medoxomil.Approved, Investigational
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Guanfacine.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Guanfacine.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Guanfacine is combined with Barbital.Illicit
BarnidipineGuanfacine may increase the antihypertensive activities of Barnidipine.Approved
BefunololGuanfacine may increase the atrioventricular blocking (AV block) activities of Befunolol.Experimental
BenazeprilGuanfacine may increase the hypotensive activities of Benazepril.Approved, Investigational
BendroflumethiazideGuanfacine may increase the hypotensive activities of Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Guanfacine.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Guanfacine is combined with Benperidol.Approved, Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Benzocaine.Approved, Investigational
Benzyl alcoholThe risk or severity of adverse effects can be increased when Guanfacine is combined with Benzyl alcohol.Approved
Benzylpenicilloyl PolylysineGuanfacine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BepridilGuanfacine may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BeractantGuanfacine may increase the bradycardic activities of Beractant.Approved
BetaxololGuanfacine may increase the atrioventricular blocking (AV block) activities of Betaxolol.Approved, Investigational
BethanidineBethanidine may increase the hypotensive activities of Guanfacine.Approved
BevantololGuanfacine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
BietaserpineGuanfacine may increase the hypotensive activities of Bietaserpine.Experimental
BimatoprostGuanfacine may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololGuanfacine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved
BoceprevirThe serum concentration of Guanfacine can be increased when it is combined with Boceprevir.Approved, Withdrawn
BopindololGuanfacine may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved
BortezomibThe metabolism of Guanfacine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Guanfacine can be decreased when it is combined with Bosentan.Approved, Investigational
BQ-123Guanfacine may increase the hypotensive activities of BQ-123.Investigational
BretyliumBretylium may increase the bradycardic activities of Guanfacine.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Guanfacine is combined with Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the antihypertensive activities of Guanfacine.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Guanfacine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Guanfacine.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Guanfacine is combined with Bromisoval.Experimental
BromocriptineBromocriptine may increase the hypertensive and vasoconstricting activities of Guanfacine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Guanfacine is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Guanfacine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Guanfacine is combined with Brotizolam.Approved, Investigational, Withdrawn
BucindololGuanfacine may increase the atrioventricular blocking (AV block) activities of Bucindolol.Investigational
BufuralolGuanfacine may increase the atrioventricular blocking (AV block) activities of Bufuralol.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Guanfacine.Approved
BunazosinBunazosin may decrease the vasoconstricting activities of Guanfacine.Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Guanfacine.Approved, Investigational
BupranololGuanfacine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
BuprenorphineGuanfacine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Guanfacine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Guanfacine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Guanfacine.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Guanfacine is combined with Butamben.Approved, Withdrawn
ButethalThe risk or severity of adverse effects can be increased when Guanfacine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Guanfacine.Approved, Illicit, Vet Approved
ButriptylineButriptyline may decrease the antihypertensive activities of Guanfacine.Approved
CabergolineCabergoline may increase the hypertensive and vasoconstricting activities of Guanfacine.Approved
CadralazineGuanfacine may increase the hypotensive activities of Cadralazine.Experimental
CafedrineGuanfacine may increase the hypotensive activities of Cafedrine.Investigational
CalfactantGuanfacine may increase the bradycardic activities of Calfactant.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Guanfacine is combined with Canagliflozin.Approved
CandesartanGuanfacine may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilGuanfacine may increase the hypotensive activities of Candesartan cilexetil.Approved
CandoxatrilGuanfacine may increase the hypotensive activities of Candoxatril.Experimental
CanertinibThe risk or severity of adverse effects can be increased when Guanfacine is combined with Canertinib.Investigational
CapecitabineThe metabolism of Guanfacine can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilGuanfacine may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe serum concentration of Guanfacine can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Guanfacine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Guanfacine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Guanfacine is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Guanfacine.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Guanfacine.Withdrawn
CarteololGuanfacine may increase the atrioventricular blocking (AV block) activities of Carteolol.Approved
CarvedilolGuanfacine may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved, Investigational
CeliprololGuanfacine may increase the atrioventricular blocking (AV block) activities of Celiprolol.Approved, Investigational
CeritinibGuanfacine may increase the bradycardic activities of Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Guanfacine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Guanfacine is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChloramphenicolThe metabolism of Guanfacine can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Guanfacine.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Guanfacine is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Chloroprocaine.Approved
ChlorothiazideGuanfacine may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Guanfacine.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Guanfacine is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorthalidoneGuanfacine may increase the hypotensive activities of Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Guanfacine.Approved
CholecalciferolThe metabolism of Guanfacine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CicletanineGuanfacine may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilGuanfacine may increase the hypotensive activities of Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Guanfacine.Approved, Investigational
CimetidineThe metabolism of Guanfacine can be decreased when combined with Cimetidine.Approved, Investigational
CinchocaineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Cinchocaine.Approved, Vet Approved
CitalopramThe metabolism of Guanfacine can be decreased when combined with Citalopram.Approved
ClarithromycinThe serum concentration of Guanfacine can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Guanfacine can be decreased when combined with Clemastine.Approved, Investigational
ClevidipineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Clevidipine.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Guanfacine.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Guanfacine.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Guanfacine.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when Guanfacine is combined with clomethiazole.Investigational
ClomipramineClomipramine may decrease the antihypertensive activities of Guanfacine.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Guanfacine is combined with Clonazepam.Approved, Illicit
ClonidineClonidine may increase the hypotensive activities of Guanfacine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Guanfacine is combined with Clopenthixol.Experimental
CloranololGuanfacine may increase the atrioventricular blocking (AV block) activities of Cloranolol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Guanfacine.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Guanfacine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Guanfacine.Approved
CobicistatThe serum concentration of Guanfacine can be increased when it is combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Guanfacine.Approved, Illicit
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Guanfacine.Approved, Investigational
CrisaboroleThe metabolism of Guanfacine can be decreased when combined with Crisaborole.Approved, Investigational
CrizotinibThe metabolism of Guanfacine can be decreased when combined with Crizotinib.Approved
CryptenamineGuanfacine may increase the hypotensive activities of Cryptenamine.Approved
CurcuminThe serum concentration of Guanfacine can be increased when it is combined with Curcumin.Approved, Investigational
CyclizineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Guanfacine.Approved
CyclopenthiazideGuanfacine may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclopropaneThe risk or severity of adverse effects can be increased when Guanfacine is combined with Cyclopropane.Experimental
CyclosporineThe metabolism of Guanfacine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideGuanfacine may increase the hypotensive activities of Cyclothiazide.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Guanfacine.Approved
DabrafenibThe serum concentration of Guanfacine can be decreased when it is combined with Dabrafenib.Approved, Investigational
DantroleneThe risk or severity of adverse effects can be increased when Guanfacine is combined with Dantrolene.Approved, Investigational
DapagliflozinThe risk or severity of adverse effects can be increased when Guanfacine is combined with Dapagliflozin.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Guanfacine is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Dapoxetine.Investigational
DarunavirThe serum concentration of Guanfacine can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Guanfacine can be increased when it is combined with Dasatinib.Approved, Investigational
DebrisoquinGuanfacine may increase the hypotensive activities of Debrisoquin.Approved, Investigational
DeferasiroxThe serum concentration of Guanfacine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelaprilGuanfacine may increase the hypotensive activities of Delapril.Investigational
DelavirdineThe metabolism of Guanfacine can be decreased when combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Guanfacine is combined with Deramciclane.Investigational
DeserpidineGuanfacine may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Guanfacine.Approved
DesipramineDesipramine may decrease the antihypertensive activities of Guanfacine.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Guanfacine.Approved, Investigational
DesvenlafaxineDesvenlafaxine may increase the tachycardic activities of Guanfacine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Guanfacine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Guanfacine.Approved, Vet Approved
DextroamphetamineDextroamphetamine may decrease the vasoconstricting activities of Guanfacine.Approved, Illicit
DextromoramideThe risk or severity of adverse effects can be increased when Guanfacine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Guanfacine is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Guanfacine.Approved, Illicit, Investigational, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Guanfacine.Approved
DibenzepinDibenzepin may decrease the antihypertensive activities of Guanfacine.Experimental
DiclofenamideThe risk or severity of adverse effects can be increased when Guanfacine is combined with Diclofenamide.Approved, Investigational
Diethyl etherThe risk or severity of adverse effects can be increased when Guanfacine is combined with Diethyl ether.Experimental
DiethylnorspermineGuanfacine may increase the hypotensive activities of Diethylnorspermine.Investigational
DifenoxinThe risk or severity of adverse effects can be increased when Guanfacine is combined with Difenoxin.Approved, Illicit
DigoxinDigoxin may increase the bradycardic activities of Guanfacine.Approved
DihydralazineGuanfacine may increase the hypotensive activities of Dihydralazine.Approved, Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Guanfacine.Approved, Illicit
DihydroergotamineDihydroergotamine may increase the hypertensive and vasoconstricting activities of Guanfacine.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Guanfacine can be decreased when combined with Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Guanfacine.Approved
DimetacrineDimetacrine may decrease the antihypertensive activities of Guanfacine.Approved, Withdrawn
DinutuximabThe risk or severity of adverse effects can be increased when Guanfacine is combined with Dinutuximab.Approved, Investigational
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Guanfacine.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Guanfacine.Approved, Illicit
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Guanfacine.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Dixyrazine.Experimental
DonepezilDonepezil may increase the bradycardic activities of Guanfacine.Approved
DoramectinThe risk or severity of adverse effects can be increased when Guanfacine is combined with Doramectin.Vet Approved
DorzolamideGuanfacine may increase the hypotensive activities of Dorzolamide.Approved
DosulepinDosulepin may decrease the antihypertensive activities of Guanfacine.Approved
DoxazosinDoxazosin may decrease the vasoconstricting activities of Guanfacine.Approved
DoxepinDoxepin may decrease the antihypertensive activities of Guanfacine.Approved, Investigational
DoxycyclineThe metabolism of Guanfacine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Guanfacine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Guanfacine is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Guanfacine.Approved, Illicit
DronedaroneThe metabolism of Guanfacine can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Guanfacine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Guanfacine is combined with Drotebanol.Experimental, Illicit
DuloxetineGuanfacine may increase the orthostatic hypotensive activities of Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Guanfacine is combined with Ecopipam.Investigational
EfavirenzThe metabolism of Guanfacine can be decreased when combined with Efavirenz.Approved, Investigational
EfonidipineGuanfacine may increase the hypotensive activities of Efonidipine.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Guanfacine is combined with Eltanolone.Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Guanfacine is combined with Empagliflozin.Approved
EnalaprilGuanfacine may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatGuanfacine may increase the hypotensive activities of Enalaprilat.Approved
EndralazineGuanfacine may increase the hypotensive activities of Endralazine.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Guanfacine is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Guanfacine.Approved, Investigational
EnzalutamideThe serum concentration of Guanfacine can be decreased when it is combined with Enzalutamide.Approved
EpanololGuanfacine may increase the atrioventricular blocking (AV block) activities of Epanolol.Experimental
EpinephrineEpinephrine may decrease the vasoconstricting activities of Guanfacine.Approved, Vet Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Guanfacine.Approved
EpoprostenolGuanfacine may increase the hypotensive activities of Epoprostenol.Approved
EprosartanGuanfacine may increase the hypotensive activities of Eprosartan.Approved
Ergoloid mesylateErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Guanfacine.Approved
ErgonovineErgonovine may increase the hypertensive and vasoconstricting activities of Guanfacine.Approved
ErgotamineErgotamine may increase the hypertensive and vasoconstricting activities of Guanfacine.Approved
ErythromycinThe metabolism of Guanfacine can be decreased when combined with Erythromycin.Approved, Investigational, Vet Approved
EsatenololGuanfacine may increase the atrioventricular blocking (AV block) activities of Esatenolol.Experimental
EscitalopramThe risk or severity of adverse effects can be increased when Guanfacine is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe metabolism of Guanfacine can be decreased when combined with Eslicarbazepine acetate.Approved
EsmololGuanfacine may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved
EsomeprazoleThe metabolism of Guanfacine can be decreased when combined with Esomeprazole.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Guanfacine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Guanfacine.Approved, Investigational
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Guanfacine.Approved, Investigational
EthanolEthanol may increase the central nervous system depressant (CNS depressant) activities of Guanfacine.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Guanfacine is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Guanfacine.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Guanfacine.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Guanfacine is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Guanfacine is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Guanfacine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Guanfacine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Guanfacine is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Guanfacine is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Etorphine.Illicit, Vet Approved
EtravirineThe metabolism of Guanfacine can be decreased when combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Ezogabine.Approved, Investigational
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Guanfacine.Approved
FelodipineGuanfacine may increase the hypotensive activities of Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenoldopamGuanfacine may increase the hypotensive activities of Fenoldopam.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Guanfacine.Approved, Illicit, Investigational, Vet Approved
Ferulic acidGuanfacine may increase the hypotensive activities of Ferulic acid.Experimental
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Guanfacine.Approved, Investigational
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Guanfacine.Approved, Investigational
FingolimodGuanfacine may increase the bradycardic activities of Fingolimod.Approved, Investigational
FlibanserinThe risk or severity of adverse effects can be increased when Guanfacine is combined with Flibanserin.Approved, Investigational
FloxuridineThe metabolism of Guanfacine can be decreased when combined with Floxuridine.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Guanfacine is combined with Fluanisone.Experimental
FluconazoleThe metabolism of Guanfacine can be decreased when combined with Fluconazole.Approved, Investigational
FludiazepamThe risk or severity of adverse effects can be increased when Guanfacine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Guanfacine is combined with Flunitrazepam.Approved, Illicit
FluorouracilThe metabolism of Guanfacine can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Guanfacine can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Guanfacine.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Guanfacine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Guanfacine.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Guanfacine is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Guanfacine.Approved
FluvastatinThe metabolism of Guanfacine can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Guanfacine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Guanfacine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Guanfacine can be increased when it is combined with Fosaprepitant.Approved
FosinoprilGuanfacine may increase the hypotensive activities of Fosinopril.Approved
FosphenytoinThe serum concentration of Guanfacine can be decreased when it is combined with Fosphenytoin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Guanfacine is combined with Fospropofol.Approved, Illicit, Investigational
FostamatinibFostamatinib may increase the antihypertensive activities of Guanfacine.Approved, Investigational
FurazolidoneFurazolidone may increase the hypotensive activities of Guanfacine.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Guanfacine.Approved, Vet Approved
Fusidic AcidThe serum concentration of Guanfacine can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Guanfacine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Guanfacine is combined with Gabapentin Enacarbil.Approved, Investigational
GalantamineGalantamine may increase the bradycardic activities of Guanfacine.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Guanfacine.Approved, Illicit, Investigational
GemfibrozilThe metabolism of Guanfacine can be decreased when combined with Gemfibrozil.Approved
GepironeThe risk or severity of adverse effects can be increased when Guanfacine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Guanfacine is combined with Glutethimide.Approved, Illicit
GuanabenzGuanfacine may increase the hypotensive activities of Guanabenz.Approved, Investigational
GuanadrelGuanfacine may increase the hypotensive activities of Guanadrel.Approved
GuanazodineGuanfacine may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanfacine may increase the hypotensive activities of Guanethidine.Approved
GuanoclorGuanfacine may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzGuanfacine may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanGuanfacine may increase the hypotensive activities of Guanoxan.Experimental
HalazepamThe risk or severity of adverse effects can be increased when Guanfacine is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Guanfacine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Guanfacine.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Guanfacine.Experimental
HeroinThe risk or severity of adverse effects can be increased when Guanfacine is combined with Heroin.Approved, Illicit, Investigational
HexamethoniumGuanfacine may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Guanfacine is combined with Hexobarbital.Approved
HyaluronidaseHyaluronidase may increase the vasoconstricting activities of Guanfacine.Approved, Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Guanfacine.Experimental
HydralazineGuanfacine may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideGuanfacine may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneGuanfacine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideGuanfacine may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Guanfacine.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Guanfacine.Approved
IdelalisibThe serum concentration of Guanfacine can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Guanfacine is combined with Iloperidone.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Guanfacine.Approved, Investigational
ImatinibThe metabolism of Guanfacine can be decreased when combined with Imatinib.Approved
ImidaprilGuanfacine may increase the hypotensive activities of Imidapril.Investigational
ImipramineImipramine may decrease the antihypertensive activities of Guanfacine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Indalpine.Investigational, Withdrawn
IndapamideGuanfacine may increase the hypotensive activities of Indapamide.Approved
IndenololGuanfacine may increase the atrioventricular blocking (AV block) activities of Indenolol.Withdrawn
IndinavirThe serum concentration of Guanfacine can be increased when it is combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Guanfacine is combined with Indiplon.Investigational
IndoraminGuanfacine may increase the hypotensive activities of Indoramin.Withdrawn
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Guanfacine.Approved, Investigational
IprindoleIprindole may decrease the antihypertensive activities of Guanfacine.Experimental
IproclozideIproclozide may increase the hypotensive activities of Guanfacine.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Guanfacine.Withdrawn
IrbesartanThe metabolism of Guanfacine can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoleThe serum concentration of Guanfacine can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Guanfacine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Guanfacine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Guanfacine.Approved, Vet Approved
IsoniazidThe metabolism of Guanfacine can be decreased when combined with Isoniazid.Approved, Investigational
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Guanfacine.Approved, Investigational
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Guanfacine is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe metabolism of Guanfacine can be decreased when combined with Isradipine.Approved, Investigational
ItraconazoleThe serum concentration of Guanfacine can be increased when it is combined with Itraconazole.Approved, Investigational
IvabradineGuanfacine may increase the bradycardic activities of Ivabradine.Approved
IvacaftorThe serum concentration of Guanfacine can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Guanfacine.Approved, Vet Approved
KetanserinGuanfacine may increase the hypotensive activities of Ketanserin.Investigational
KetazolamThe risk or severity of adverse effects can be increased when Guanfacine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Guanfacine is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe serum concentration of Guanfacine can be increased when it is combined with Ketoconazole.Approved, Investigational
LabetalolGuanfacine may increase the atrioventricular blocking (AV block) activities of Labetalol.Approved
LacidipineGuanfacine may increase the hypotensive activities of Lacidipine.Approved, Investigational
LacosamideGuanfacine may increase the atrioventricular blocking (AV block) activities of Lacosamide.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Guanfacine.Approved, Investigational
LandiololGuanfacine may increase the atrioventricular blocking (AV block) activities of Landiolol.Investigational
LanreotideGuanfacine may increase the bradycardic activities of Lanreotide.Approved
LatanoprostGuanfacine may increase the hypotensive activities of Latanoprost.Approved, Investigational
LeflunomideThe metabolism of Guanfacine can be decreased when combined with Leflunomide.Approved, Investigational
LercanidipineGuanfacine may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Guanfacine is combined with Levetiracetam.Approved, Investigational
LevobetaxololGuanfacine may increase the atrioventricular blocking (AV block) activities of Levobetaxolol.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Guanfacine is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Guanfacine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Levocetirizine.Approved
LevodopaGuanfacine may increase the orthostatic hypotensive activities of Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Guanfacine is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the tachycardic activities of Guanfacine.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Guanfacine.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Guanfacine.Approved, Investigational
LidocaineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Lidocaine.Approved, Vet Approved
LinsidomineGuanfacine may increase the hypotensive activities of Linsidomine.Experimental
LisdexamfetamineLisdexamfetamine may decrease the vasoconstricting activities of Guanfacine.Approved, Investigational
LisinoprilGuanfacine may increase the hypotensive activities of Lisinopril.Approved, Investigational
Lithium cationThe risk or severity of adverse effects can be increased when Guanfacine is combined with Lithium.Experimental
LobeglitazoneThe metabolism of Guanfacine can be decreased when combined with Lobeglitazone.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Guanfacine is combined with Lofentanil.Illicit
LofepramineLofepramine may decrease the antihypertensive activities of Guanfacine.Experimental
LofexidineThe therapeutic efficacy of Guanfacine can be increased when used in combination with Lofexidine.Approved, Investigational
LopinavirThe serum concentration of Guanfacine can be increased when it is combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Guanfacine is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Guanfacine.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Guanfacine.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Guanfacine is combined with Lormetazepam.Approved
LorpiprazoleThe serum concentration of Guanfacine can be increased when it is combined with Lorpiprazole.Approved
LosartanThe metabolism of Guanfacine can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Guanfacine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Guanfacine.Approved
LucinactantGuanfacine may increase the bradycardic activities of Lucinactant.Approved, Investigational
LuliconazoleThe serum concentration of Guanfacine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Guanfacine can be decreased when it is combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Guanfacine.Approved, Investigational
MacitentanGuanfacine may increase the hypotensive activities of Macitentan.Approved
Magnesium sulfateThe therapeutic efficacy of Guanfacine can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineGuanfacine may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Guanfacine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Guanfacine.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Guanfacine.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Guanfacine is combined with Mebicar.Experimental
MecamylamineMecamylamine may increase the hypotensive activities of Guanfacine.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Guanfacine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Guanfacine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Guanfacine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelitracenMelitracen may decrease the antihypertensive activities of Guanfacine.Experimental, Investigational
MelperoneThe risk or severity of adverse effects can be increased when Guanfacine is combined with Melperone.Approved, Investigational
MepindololGuanfacine may increase the atrioventricular blocking (AV block) activities of Mepindolol.Experimental
MepivacaineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Guanfacine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Guanfacine is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Mesoridazine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Guanfacine.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Guanfacine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Guanfacine is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Guanfacine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Guanfacine is combined with Methaqualone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Guanfacine.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Guanfacine.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Guanfacine.Approved
MethoserpidineGuanfacine may increase the hypotensive activities of Methoserpidine.Experimental
MethotrimeprazineGuanfacine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Guanfacine is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Guanfacine is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Guanfacine.Approved
MethyldopaGuanfacine may increase the hypotensive activities of Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Methylecgonine.Experimental
Methylene blueMethylene blue may increase the hypotensive activities of Guanfacine.Approved, Investigational
MethylergometrineMethylergometrine may increase the hypertensive and vasoconstricting activities of Guanfacine.Approved
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Guanfacine.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Guanfacine is combined with Methylphenobarbital.Approved
MetipranololGuanfacine may increase the hypotensive activities of Metipranolol.Approved
MetolazoneGuanfacine may increase the hypotensive activities of Metolazone.Approved
MetoprololGuanfacine may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved, Investigational
MetyrosineGuanfacine may increase the sedative activities of Metyrosine.Approved
MianserinThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Mianserin.Approved, Investigational
MibefradilGuanfacine may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Guanfacine.Approved, Illicit
MidostaurinThe metabolism of Guanfacine can be decreased when combined with Midostaurin.Approved, Investigational
MifepristoneThe serum concentration of Guanfacine can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranMilnacipran may increase the tachycardic activities of Guanfacine.Approved, Investigational
MinaprineMinaprine may increase the hypotensive activities of Guanfacine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Guanfacine.Approved, Investigational
MinoxidilMinoxidil may increase the hypotensive activities of Guanfacine.Approved, Investigational
MirodenafilMirodenafil may increase the antihypertensive activities of Guanfacine.Investigational
MirtazapineMirtazapine may decrease the antihypertensive activities of Guanfacine.Approved
MitotaneThe serum concentration of Guanfacine can be decreased when it is combined with Mitotane.Approved
MoclobemideThe metabolism of Guanfacine can be decreased when combined with Moclobemide.Approved, Investigational
ModafinilThe metabolism of Guanfacine can be decreased when combined with Modafinil.Approved, Investigational
MoexiprilGuanfacine may increase the hypotensive activities of Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Guanfacine is combined with Molindone.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Guanfacine.Approved, Investigational
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Guanfacine.Approved, Investigational
MoxonidineGuanfacine may increase the hypotensive activities of Moxonidine.Approved, Investigational
MuzolimineGuanfacine may increase the hypotensive activities of Muzolimine.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Guanfacine.Approved, Investigational
NadololGuanfacine may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved
NaftopidilGuanfacine may increase the hypotensive activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Guanfacine.Approved
NebivololGuanfacine may increase the atrioventricular blocking (AV block) activities of Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Guanfacine can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Guanfacine can be increased when it is combined with Nelfinavir.Approved
NesiritideThe risk or severity of adverse effects can be increased when Guanfacine is combined with Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Guanfacine can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe serum concentration of Guanfacine can be decreased when it is combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Guanfacine.Withdrawn
NicardipineThe metabolism of Guanfacine can be decreased when combined with Nicardipine.Approved, Investigational
NicergolineNicergoline may decrease the vasoconstricting activities of Guanfacine.Approved, Investigational
NicorandilNicorandil may increase the hypotensive activities of Guanfacine.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Nifedipine.Approved
NiguldipineGuanfacine may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe metabolism of Guanfacine can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineGuanfacine may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimodipineGuanfacine may increase the hypotensive activities of Nimodipine.Approved, Investigational
NisoldipineGuanfacine may increase the hypotensive activities of Nisoldipine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Guanfacine.Approved
NitrendipineGuanfacine may increase the hypotensive activities of Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Guanfacine.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Guanfacine.Approved, Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Guanfacine.Approved, Investigational
Nitrous acidThe risk or severity of adverse effects can be increased when Nitrous acid is combined with Guanfacine.Approved, Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Guanfacine.Approved, Vet Approved
NordazepamThe risk or severity of adverse effects can be increased when Guanfacine is combined with Nordazepam.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Guanfacine is combined with Norflurane.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Guanfacine is combined with Normethadone.Approved, Illicit
NortriptylineNortriptyline may decrease the antihypertensive activities of Guanfacine.Approved
ObinutuzumabGuanfacine may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OctamoxinOctamoxin may increase the hypotensive activities of Guanfacine.Withdrawn
OctreotideOctreotide may increase the bradycardic activities of Guanfacine.Approved, Investigational
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Guanfacine.Approved, Investigational
OlaparibThe metabolism of Guanfacine can be decreased when combined with Olaparib.Approved
OlmesartanGuanfacine may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Guanfacine.Approved
OmapatrilatGuanfacine may increase the hypotensive activities of Omapatrilat.Investigational
OmeprazoleThe metabolism of Guanfacine can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe risk or severity of adverse effects can be increased when Guanfacine is combined with Ondansetron.Approved
OpipramolOpipramol may decrease the antihypertensive activities of Guanfacine.Investigational
OpiumThe risk or severity of adverse effects can be increased when Guanfacine is combined with Opium.Approved, Illicit
OrphenadrineGuanfacine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Guanfacine is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Guanfacine can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Guanfacine.Approved
OxprenololGuanfacine may increase the atrioventricular blocking (AV block) activities of Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Oxybuprocaine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Guanfacine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Guanfacine.Approved, Investigational, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Guanfacine.Approved, Vet Approved
PalbociclibThe serum concentration of Guanfacine can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Guanfacine.Approved
PantoprazoleThe metabolism of Guanfacine can be decreased when combined with Pantoprazole.Approved
PapaverineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Papaverine.Approved, Investigational
ParaldehydeGuanfacine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
PargylinePargyline may increase the hypotensive activities of Guanfacine.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Paroxetine.Approved, Investigational
PasireotideGuanfacine may increase the bradycardic activities of Pasireotide.Approved
PenbutololGuanfacine may increase the atrioventricular blocking (AV block) activities of Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Guanfacine is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Guanfacine.Approved, Vet Approved
PentobarbitalThe serum concentration of Guanfacine can be decreased when it is combined with Pentobarbital.Approved, Investigational, Vet Approved
PentoliniumGuanfacine may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Guanfacine.Approved, Investigational
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Guanfacine.Approved
PerazineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Perazine.Approved, Investigational
PerindoprilGuanfacine may increase the hypotensive activities of Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Guanfacine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Guanfacine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Guanfacine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Phenazocine.Experimental
PhenelzinePhenelzine may increase the hypotensive activities of Guanfacine.Approved
PhenibutThe risk or severity of adverse effects can be increased when Guanfacine is combined with Phenibut.Experimental
PheniprazinePheniprazine may increase the hypotensive activities of Guanfacine.Withdrawn
PhenobarbitalThe serum concentration of Guanfacine can be decreased when it is combined with Phenobarbital.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Phenoperidine.Experimental
PhenoxybenzamineGuanfacine may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Guanfacine is combined with Phenoxyethanol.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Guanfacine.Withdrawn
PhentolamineGuanfacine may increase the hypotensive activities of Phentolamine.Approved
PhenytoinThe serum concentration of Guanfacine can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Guanfacine.Approved
PinacidilGuanfacine may increase the hypotensive activities of Pinacidil.Approved
PindololGuanfacine may increase the atrioventricular blocking (AV block) activities of Pindolol.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Guanfacine.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Guanfacine is combined with Piritramide.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Guanfacine.Approved
PitolisantThe serum concentration of Guanfacine can be decreased when it is combined with Pitolisant.Approved, Investigational
PivhydrazinePivhydrazine may increase the hypotensive activities of Guanfacine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Guanfacine is combined with Pizotifen.Approved
Platelet Activating FactorGuanfacine may increase the atrioventricular blocking (AV block) activities of Platelet Activating Factor.Experimental
PolythiazideGuanfacine may increase the hypotensive activities of Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Guanfacine is combined with Pomalidomide.Approved
Poractant alfaGuanfacine may increase the bradycardic activities of Poractant alfa.Approved
PosaconazoleThe serum concentration of Guanfacine can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PractololGuanfacine may increase the atrioventricular blocking (AV block) activities of Practolol.Approved
PramipexoleGuanfacine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Guanfacine is combined with Prazepam.Approved, Illicit
PrazosinPrazosin may decrease the vasoconstricting activities of Guanfacine.Approved
PregabalinThe therapeutic efficacy of Guanfacine can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Prilocaine.Approved
PrimidoneThe serum concentration of Guanfacine can be decreased when it is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Guanfacine.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Guanfacine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Guanfacine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Promethazine.Approved, Investigational
PropafenoneGuanfacine may increase the atrioventricular blocking (AV block) activities of Propafenone.Approved
PropanididThe risk or severity of adverse effects can be increased when Guanfacine is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Proparacaine.Approved, Vet Approved
PropericiazinePropericiazine may decrease the vasoconstricting activities of Guanfacine.Approved, Investigational
PropiomazinePropiomazine may decrease the vasoconstricting activities of Guanfacine.Approved
PropiverinePropiverine may decrease the vasoconstricting activities of Guanfacine.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Guanfacine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Propoxycaine.Approved
PropranololGuanfacine may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved, Investigational
ProtriptylineProtriptyline may decrease the antihypertensive activities of Guanfacine.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Guanfacine is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Guanfacine is combined with PSD502.Investigational
PyrimethamineThe metabolism of Guanfacine can be decreased when combined with Pyrimethamine.Approved, Investigational, Vet Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Guanfacine.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Quetiapine.Approved
QuinaprilGuanfacine may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinidineQuinidine may decrease the vasoconstricting activities of Guanfacine.Approved, Investigational
QuinineThe metabolism of Guanfacine can be decreased when combined with Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Quinisocaine.Experimental
RacepinephrineRacepinephrine may decrease the vasoconstricting activities of Guanfacine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Guanfacine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Guanfacine.Approved, Investigational
RamiprilGuanfacine may increase the hypotensive activities of Ramipril.Approved
RanolazineThe metabolism of Guanfacine can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Guanfacine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Guanfacine.Approved
RemikirenGuanfacine may increase the hypotensive activities of Remikiren.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Guanfacine is combined with Remoxipride.Approved, Withdrawn
RescinnamineGuanfacine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Guanfacine.Approved, Investigational
RifabutinThe serum concentration of Guanfacine can be decreased when it is combined with Rifabutin.Approved, Investigational
RifampicinThe serum concentration of Guanfacine can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Guanfacine can be decreased when it is combined with Rifapentine.Approved, Investigational
RilmenidineGuanfacine may increase the hypotensive activities of Rilmenidine.Approved, Investigational
RiociguatGuanfacine may increase the hypotensive activities of Riociguat.Approved
RisperidoneGuanfacine may increase the hypotensive activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Guanfacine is combined with Ritanserin.Investigational
RituximabGuanfacine may increase the hypotensive activities of Rituximab.Approved
RivastigmineRivastigmine may increase the bradycardic activities of Guanfacine.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Romifidine.Vet Approved
RopiniroleGuanfacine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Guanfacine.Approved
RotigotineGuanfacine may increase the sedative activities of Rotigotine.Approved
RucaparibThe metabolism of Guanfacine can be decreased when combined with Rucaparib.Approved, Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Guanfacine.Approved
RuxolitinibRuxolitinib may increase the bradycardic activities of Guanfacine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Guanfacine.Approved
SafrazineSafrazine may increase the hypotensive activities of Guanfacine.Withdrawn
SaprisartanGuanfacine may increase the hypotensive activities of Saprisartan.Experimental
SaquinavirThe serum concentration of Guanfacine can be increased when it is combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Sarilumab.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Guanfacine.Approved, Investigational
SecobarbitalThe metabolism of Guanfacine can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Guanfacine.Approved, Investigational, Vet Approved
SelexipagGuanfacine may increase the hypotensive activities of Selexipag.Approved
SepranoloneThe risk or severity of adverse effects can be increased when Guanfacine is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Guanfacine is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe metabolism of Guanfacine can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Guanfacine.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Guanfacine.Approved, Investigational
SilodosinSilodosin may decrease the vasoconstricting activities of Guanfacine.Approved
SiltuximabThe serum concentration of Guanfacine can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Guanfacine can be increased when it is combined with Simeprevir.Approved
SitaxentanGuanfacine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Guanfacine.Approved
SorafenibThe metabolism of Guanfacine can be decreased when combined with Sorafenib.Approved, Investigational
SotalolGuanfacine may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved
SpiraprilGuanfacine may increase the hypotensive activities of Spirapril.Approved
SpironolactoneSpironolactone may decrease the vasoconstricting activities of Guanfacine.Approved
St. John's WortThe serum concentration of Guanfacine can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Guanfacine can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Guanfacine.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Guanfacine.Approved, Investigational
SulfadiazineThe metabolism of Guanfacine can be decreased when combined with Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleThe metabolism of Guanfacine can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Guanfacine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Guanfacine is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Guanfacine is combined with Sultopride.Experimental
SuvorexantGuanfacine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Guanfacine.Approved, Investigational
TalinololGuanfacine may increase the atrioventricular blocking (AV block) activities of Talinolol.Investigational
TamsulosinTamsulosin may decrease the vasoconstricting activities of Guanfacine.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Guanfacine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Guanfacine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Guanfacine is combined with Tasimelteon.Approved, Investigational
TelaprevirThe serum concentration of Guanfacine can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelithromycinThe serum concentration of Guanfacine can be increased when it is combined with Telithromycin.Approved
TelmisartanGuanfacine may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Guanfacine.Approved, Investigational
TemocaprilGuanfacine may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerazosinTerazosin may decrease the vasoconstricting activities of Guanfacine.Approved
TerbutalineGuanfacine may increase the atrioventricular blocking (AV block) activities of Terbutaline.Approved
TerlipressinGuanfacine may increase the hypotensive activities of Terlipressin.Approved, Investigational
TertatololGuanfacine may increase the atrioventricular blocking (AV block) activities of Tertatolol.Experimental
TetrabenazineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Tetrabenazine.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineGuanfacine may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Guanfacine is combined with Tetrodotoxin.Investigational
ThalidomideGuanfacine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheodrenalineGuanfacine may increase the hypotensive activities of Theodrenaline.Investigational
TheophyllineTheophylline may increase the antihypertensive activities of Guanfacine.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Guanfacine is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Guanfacine is combined with Thiopental.Approved, Vet Approved
ThioproperazineThioproperazine may decrease the vasoconstricting activities of Guanfacine.Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Guanfacine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Guanfacine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Guanfacine.Approved, Investigational
TianeptineTianeptine may decrease the antihypertensive activities of Guanfacine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Guanfacine is combined with Tiapride.Approved, Investigational
TiboloneGuanfacine may increase the hypotensive activities of Tibolone.Approved, Investigational
TicagrelorThe metabolism of Guanfacine can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Guanfacine can be decreased when combined with Ticlopidine.Approved
TicrynafenGuanfacine may increase the hypotensive activities of Ticrynafen.Withdrawn
TiletamineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Tilidine.Experimental
TimololGuanfacine may increase the atrioventricular blocking (AV block) activities of Timolol.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Guanfacine.Approved, Investigational
TocilizumabThe serum concentration of Guanfacine can be decreased when it is combined with Tocilizumab.Approved
TofacitinibTofacitinib may increase the bradycardic activities of Guanfacine.Approved, Investigational
TolazolineGuanfacine may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideThe metabolism of Guanfacine can be decreased when combined with Tolbutamide.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Guanfacine.Approved, Withdrawn
TolonidineGuanfacine may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Guanfacine.Approved
TopiramateThe metabolism of Guanfacine can be decreased when combined with Topiramate.Approved
TopiroxostatThe metabolism of Guanfacine can be decreased when combined with Topiroxostat.Approved, Investigational
TorasemideGuanfacine may increase the hypotensive activities of Torasemide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Guanfacine.Approved, Investigational
TrandolaprilGuanfacine may increase the hypotensive activities of Trandolapril.Approved
TranylcypromineThe metabolism of Guanfacine can be decreased when combined with Tranylcypromine.Approved, Investigational
TravoprostGuanfacine may increase the hypotensive activities of Travoprost.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Guanfacine is combined with Trazodone.Approved, Investigational
TreprostinilGuanfacine may increase the hypotensive activities of Treprostinil.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Guanfacine.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Guanfacine.Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Guanfacine.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Guanfacine is combined with Tricaine methanesulfonate.Vet Approved
TrichlormethiazideGuanfacine may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Guanfacine is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Guanfacine.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Guanfacine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Triflupromazine.Approved, Vet Approved
TrimazosinGuanfacine may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanGuanfacine may increase the hypotensive activities of Trimethaphan.Approved, Investigational
TrimethoprimThe metabolism of Guanfacine can be decreased when combined with Trimethoprim.Approved, Vet Approved
TrimipramineTrimipramine may decrease the antihypertensive activities of Guanfacine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Guanfacine.Approved
UdenafilUdenafil may increase the antihypertensive activities of Guanfacine.Approved, Investigational
UnoprostoneGuanfacine may increase the hypotensive activities of Unoprostone.Approved, Investigational
UrapidilUrapidil may decrease the vasoconstricting activities of Guanfacine.Investigational
Valproic AcidThe serum concentration of Valproic Acid can be increased when it is combined with Guanfacine.Approved, Investigational
ValsartanThe metabolism of Guanfacine can be decreased when combined with Valsartan.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Guanfacine.Approved
VemurafenibThe serum concentration of Guanfacine can be decreased when it is combined with Vemurafenib.Approved
VenlafaxineVenlafaxine may increase the tachycardic activities of Guanfacine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Guanfacine is combined with Veralipride.Experimental
VerapamilThe metabolism of Guanfacine can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Guanfacine is combined with Vigabatrin.Approved
VincamineGuanfacine may increase the hypotensive activities of Vincamine.Experimental
VinpocetineGuanfacine may increase the hypotensive activities of Vinpocetine.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Guanfacine is combined with Vinyl ether.Experimental
VoriconazoleThe serum concentration of Guanfacine can be increased when it is combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Vortioxetine.Approved, Investigational
XenonThe risk or severity of adverse effects can be increased when Guanfacine is combined with Xenon.Experimental
XipamideGuanfacine may increase the hypotensive activities of Xipamide.Experimental
XylazineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Xylazine.Vet Approved
XylometazolineGuanfacine may increase the hypotensive activities of Xylometazoline.Approved, Investigational
YohimbineYohimbine may decrease the antihypertensive activities of Guanfacine.Approved, Investigational, Vet Approved
ZafirlukastThe metabolism of Guanfacine can be decreased when combined with Zafirlukast.Approved, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Guanfacine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Guanfacine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Guanfacine can be decreased when combined with Ziprasidone.Approved
ZofenoprilGuanfacine may increase the hypotensive activities of Zofenopril.Experimental
ZolazepamThe risk or severity of adverse effects can be increased when Guanfacine is combined with Zolazepam.Vet Approved
ZolpidemGuanfacine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Guanfacine.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Guanfacine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Zotepine.Approved, Investigational, Withdrawn
ZucapsaicinThe metabolism of Guanfacine can be decreased when combined with Zucapsaicin.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Guanfacine.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

U.S. Patent 3,632,645.

General References
Not Available
External Links
Human Metabolome Database
HMDB0015153
KEGG Compound
C07037
PubChem Compound
3519
PubChem Substance
46506169
ChemSpider
3399
BindingDB
81984
ChEBI
5558
ChEMBL
CHEMBL862
Therapeutic Targets Database
DAP000900
PharmGKB
PA449825
IUPHAR
522
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Guanfacine
ATC Codes
C02AC02 — Guanfacine
AHFS Codes
  • 24:08.16 — Central Alpha-agonists

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers2
1CompletedBasic ScienceHealthy Volunteers1
1CompletedTreatmentAlcohol Dependent / Cocaine Dependent1
1CompletedTreatmentCannabis Dependence1
1CompletedTreatmentHigh Blood Pressure (Hypertension)1
1CompletedTreatmentPost-Traumatic Stress Disorder (PTSD)1
2Active Not RecruitingTreatmentCessation, Smoking1
2Active Not RecruitingTreatmentSmoking1
2CompletedOtherCocaine Related Disorders1
2CompletedOtherSmoking1
2CompletedTreatmentAttention Deficit Disorder With Hyperactivity2
2CompletedTreatmentGeneralized Anxiety Disorder (GAD) / Separation Anxiety / Social Phobia1
2CompletedTreatmentHemispatial Neglect / Strokes1
2CompletedTreatmentSchizotypal Personality Disorder / SPD1
2RecruitingTreatmentAlcohol Drinking1
3CompletedTreatmentAttention Deficit Disorder With Hyperactivity1
3CompletedTreatmentAttention Deficit Disorder With Hyperactivity (ADHD)4
3CompletedTreatmentAttention-Deficit/Hyperactivity Disorder2
3CompletedTreatmentGilles de la Tourette's Syndrome1
3CompletedTreatmentHigh Blood Pressure (Hypertension)1
3Not Yet RecruitingTreatmentAlzheimer's Disease (AD)1
3TerminatedTreatmentHigh Blood Pressure (Hypertension)1
4Active Not RecruitingTreatmentObstructive Sleep Apnea (OSA)1
4CompletedBasic ScienceAttention Deficit Disorder With Hyperactivity (ADHD)1
4CompletedTreatmentAdult Attention Deficit Hyperactivity Disorder (ADHD)1
4CompletedTreatmentAttention Deficit Disorder (ADD) / Childhood Aggression / Intermittent Explosive Disorder / Oppositional Defiant Disorder1
4CompletedTreatmentAttention Deficit Disorder With Hyperactivity2
4CompletedTreatmentAttention Deficit Disorder With Hyperactivity (ADHD)1
4CompletedTreatmentAttention Deficit Disorder With Hyperactivity (ADHD) / Deficient Emotional Self-Regulation (DESR)1
4CompletedTreatmentAttention Deficit Disorder With Hyperactivity (ADHD) / Reading Disability1
4CompletedTreatmentAttention-Deficit/Hyperactivity Disorder1
4CompletedTreatmentGilles de la Tourette's Syndrome / Tourette's Disorder1
4CompletedTreatmentPervasive Development Disorders1
4Not Yet RecruitingTreatmentStress Disorders1
4RecruitingTreatmentPain, Chronic1
4TerminatedTreatmentAttention Deficit Disorder (ADD) / Attention-Deficit/Hyperactivity Disorder / Sleep disorders and disturbances / Sleeplessness1
4TerminatedTreatmentPersonality Disorders / Schizotypal Personality Disorder1
4Unknown StatusTreatmentCognitive Impairments / Schizoaffective Disorders / Schizophrenic Disorders1
Not AvailableCompletedBasic ScienceNMDA Receptor Function1
Not AvailableCompletedTreatmentAttention Deficit Disorder With Hyperactivity / Autistic Disorder / Pervasive Development Disorders1
Not AvailableCompletedTreatmentCognitive Aging1
Not AvailableEnrolling by InvitationNot AvailableAttention Deficit Disorder With Hyperactivity (ADHD)1
Not AvailableNot Yet RecruitingBasic ScienceAttention Deficit Disorder With Hyperactivity (ADHD)1
Not AvailableRecruitingTreatmentAttention Deficit Disorder With Hyperactivity (ADHD)2
Not AvailableRecruitingTreatmentPain, Chronic1
Not AvailableRecruitingTreatmentPostoperative pain / Prophylaxis against postoperative nausea and vomiting1
Not AvailableUnknown StatusTreatmentBorderline Personality Disorder (BPD)1

Pharmacoeconomics

Manufacturers
  • Shire development inc
  • Amneal pharmaceutical
  • Mikah pharma llc
  • Mylan pharmaceuticals inc
  • Watson laboratories inc
  • Promius pharma llc
Packagers
  • Actavis Group
  • Advanced Pharmaceutical Services Inc.
  • Amerisource Health Services Corp.
  • Amneal Pharmaceuticals
  • Atlantic Biologicals Corporation
  • Cardinal Health
  • Industriale Chimica S.R.L.
  • Major Pharmaceuticals
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Par Pharmaceuticals
  • Patheon Inc.
  • Pharmaceutical Utilization Management Program VA Inc.
  • Pharmedix
  • Physicians Total Care Inc.
  • Promius Pharma
  • Qualitest
  • Resource Optimization and Innovation LLC
  • Shire Inc.
  • Southwood Pharmaceuticals
  • Watson Pharmaceuticals
Dosage forms
FormRouteStrength
TabletOral1 mg/1
TabletOral2 mg/1
Tablet, extended releaseOral1 mg/1
Tablet, extended releaseOral2 mg/1
Tablet, extended releaseOral3 mg/1
Tablet, extended releaseOral4 mg/1
Tablet, film coated, extended releaseOral1 mg/1
Tablet, film coated, extended releaseOral2 mg/1
Tablet, film coated, extended releaseOral3 mg/1
Tablet, film coated, extended releaseOral4 mg/1
Kit
Tablet, extended releaseOral1 mg
Tablet, extended releaseOral2 mg
Tablet, extended releaseOral3 mg
Tablet, extended releaseOral4 mg
Prices
Unit descriptionCostUnit
Intuniv 1 mg 24 Hour tablet5.72USD tablet
Intuniv 2 mg 24 Hour tablet5.72USD tablet
Intuniv 3 mg 24 Hour tablet5.72USD tablet
Intuniv 4 mg 24 Hour tablet5.72USD tablet
Intuniv er 1 mg tablet5.5USD tablet
Intuniv er 2 mg tablet5.5USD tablet
Intuniv er 3 mg tablet5.5USD tablet
Intuniv er 4 mg tablet5.5USD tablet
Tenex 2 mg tablet4.3USD tablet
Tenex 1 mg tablet2.9USD tablet
Guanfacine HCl 2 mg tablet1.22USD tablet
Guanfacine 2 mg tablet1.18USD tablet
Guanfacine HCl 1 mg tablet0.91USD tablet
Guanfacine 1 mg tablet0.87USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5854290Yes1996-03-212016-03-21Us
US6811794Yes2003-01-042023-01-04Us
US6287599Yes2001-06-202021-06-20Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)213-216U.S. Patent 3,632,645.
water solubility1892 mg/LNot Available
logP1.7Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.139 mg/mLALOGPS
logP2.28ALOGPS
logP1.74ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)12.94ChemAxon
pKa (Strongest Basic)6.65ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area78.97 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity69.63 m3·mol-1ChemAxon
Polarizability21.75 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9313
Blood Brain Barrier+0.9567
Caco-2 permeable-0.5101
P-glycoprotein substrateNon-substrate0.6778
P-glycoprotein inhibitor INon-inhibitor0.8782
P-glycoprotein inhibitor IINon-inhibitor0.9833
Renal organic cation transporterNon-inhibitor0.6443
CYP450 2C9 substrateNon-substrate0.7572
CYP450 2D6 substrateNon-substrate0.7948
CYP450 3A4 substrateNon-substrate0.6475
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.8893
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.7376
CYP450 3A4 inhibitorNon-inhibitor0.831
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6619
Ames testNon AMES toxic0.7223
CarcinogenicityNon-carcinogens0.8107
BiodegradationNot ready biodegradable0.9843
Rat acute toxicity2.7408 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9677
hERG inhibition (predictor II)Non-inhibitor0.9285
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as dichlorobenzenes. These are compounds containing a benzene with exactly two chlorine atoms attached to it.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Halobenzenes
Direct Parent
Dichlorobenzenes
Alternative Parents
Aryl chlorides / Propargyl-type 1,3-dipolar organic compounds / Carboximidamides / Organopnictogen compounds / Organooxygen compounds / Organochlorides / Imines / Hydrocarbon derivatives
Substituents
1,3-dichlorobenzene / Aryl chloride / Aryl halide / Carboximidamide / Organic 1,3-dipolar compound / Propargyl-type 1,3-dipolar organic compound / Organic nitrogen compound / Hydrocarbon derivative / Organooxygen compound / Organonitrogen compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
acetamides (CHEBI:5558)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
Gene Name
ADRA2A
Uniprot ID
P08913
Uniprot Name
Alpha-2A adrenergic receptor
Molecular Weight
48956.275 Da
References
  1. Avery RA, Franowicz JS, Studholme C, van Dyck CH, Arnsten AF: The alpha-2A-adrenoceptor agonist, guanfacine, increases regional cerebral blood flow in dorsolateral prefrontal cortex of monkeys performing a spatial working memory task. Neuropsychopharmacology. 2000 Sep;23(3):240-9. [PubMed:10942848]
  2. Sagvolden T: The alpha-2A adrenoceptor agonist guanfacine improves sustained attention and reduces overactivity and impulsiveness in an animal model of Attention-Deficit/Hyperactivity Disorder (ADHD). Behav Brain Funct. 2006 Dec 15;2:41. [PubMed:17173664]
  3. Yuan R, Wu Z, Kostenyuk IA, Burns JK: G-protein-coupled alpha2A-adrenoreceptor agonists differentially alter citrus leaf and fruit abscission by affecting expression of ACC synthase and ACC oxidase. J Exp Bot. 2005 Jul;56(417):1867-75. Epub 2005 May 31. [PubMed:15928018]
  4. Birnbaum SG, Podell DM, Arnsten AF: Noradrenergic alpha-2 receptor agonists reverse working memory deficits induced by the anxiogenic drug, FG7142, in rats. Pharmacol Biochem Behav. 2000 Nov;67(3):397-403. [PubMed:11164065]
  5. Millan MJ: Evidence that an alpha 2A-adrenoceptor subtype mediates antinociception in mice. Eur J Pharmacol. 1992 May 14;215(2-3):355-6. [PubMed:1356794]
  6. Stahl SM: Mechanism of action of alpha 2A-adrenergic agonists in attention-deficit/hyperactivity disorder with or without oppositional symptoms. J Clin Psychiatry. 2010 Mar;71(3):223-4. doi: 10.4088/JCP.09bs05899pur. [PubMed:20331927]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Epinephrine binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine...
Gene Name
ADRA2B
Uniprot ID
P18089
Uniprot Name
Alpha-2B adrenergic receptor
Molecular Weight
49565.8 Da
References
  1. Uhlen S, Wikberg JE: Delineation of rat kidney alpha 2A- and alpha 2B-adrenoceptors with [3H]RX821002 radioligand binding: computer modelling reveals that guanfacine is an alpha 2A-selective compound. Eur J Pharmacol. 1991 Sep 17;202(2):235-43. [PubMed:1666366]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Clement B, Demesmaeker M: Microsomal catalyzed N-hydroxylation of guanfacine and reduction of N-hydroxyguanfacine. Arch Pharm (Weinheim). 1997 Oct;330(9-10):303-6. [PubMed:9396389]
  2. Guillouzo A, Le Bigot JF, Guguen-Guillouzo C, Kiechel JR: Presence of phase I and phase II drug metabolizing enzymes in cultured human foetal hepatocytes. Biochem Pharmacol. 1982 Jul 15;31(14):2427-30. [PubMed:6751332]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Clement B, Demesmaeker M: Microsomal catalyzed N-hydroxylation of guanfacine and reduction of N-hydroxyguanfacine. Arch Pharm (Weinheim). 1997 Oct;330(9-10):303-6. [PubMed:9396389]
  2. Guillouzo A, Le Bigot JF, Guguen-Guillouzo C, Kiechel JR: Presence of phase I and phase II drug metabolizing enzymes in cultured human foetal hepatocytes. Biochem Pharmacol. 1982 Jul 15;31(14):2427-30. [PubMed:6751332]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Clement B, Demesmaeker M: Microsomal catalyzed N-hydroxylation of guanfacine and reduction of N-hydroxyguanfacine. Arch Pharm (Weinheim). 1997 Oct;330(9-10):303-6. [PubMed:9396389]
  2. Guillouzo A, Le Bigot JF, Guguen-Guillouzo C, Kiechel JR: Presence of phase I and phase II drug metabolizing enzymes in cultured human foetal hepatocytes. Biochem Pharmacol. 1982 Jul 15;31(14):2427-30. [PubMed:6751332]

Drug created on June 13, 2005 07:24 / Updated on July 13, 2018 01:05